Search research articles
Contact Us
Filters
Showing results (241-250 of 272) with videos related to
Page
of 28
Sort By:
British Journal of Haematology
|
January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
Lihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Blood
|
May 30, 2008
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G Till, Michael C Jensen, Jinjuan Wang, et al.
Blood
|
May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
John M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood
|
October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
John M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Plos One
|
October 19, 2018
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies
Yawen Li, Donald K Hamlin, Ming-Kuan Chyan, et al.
Hematological Oncology
|
September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status
Maika Onishi, Solomon A Graf, Leona Holmberg, et al.
Leukemia & Lymphoma
|
April 9, 2014
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity
Colin Phipps, Ajay K Gopal, Barry E Storer, et al.
Blood
|
August 10, 2019
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
Shyril O'Steen, Melissa L Comstock, Johnnie J Orozco, et al.
Blood
|
November 19, 2015
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment
Johnnie J Orozco, Aimee Kenoyer, Ethan R Balkin, et al.
Blood
|
November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies
Damian J Green, Shyril O'Steen, Yukang Lin, et al.
Page
of 28
Search research articles
Search
Showing results (241-250 of 272) with videos related to
Sort By:
Page
of 28
British Journal of Haematology
|
January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
Lihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Blood
|
May 30, 2008
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G Till, Michael C Jensen, Jinjuan Wang, et al.
Blood
|
May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
John M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Blood
|
October 29, 2005
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
John M Pagel, Frederick R Appelbaum, Janet F Eary, et al.
Plos One
|
October 19, 2018
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies
Yawen Li, Donald K Hamlin, Ming-Kuan Chyan, et al.
Hematological Oncology
|
September 20, 2014
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status
Maika Onishi, Solomon A Graf, Leona Holmberg, et al.
Leukemia & Lymphoma
|
April 9, 2014
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity
Colin Phipps, Ajay K Gopal, Barry E Storer, et al.
Blood
|
August 10, 2019
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
Shyril O'Steen, Melissa L Comstock, Johnnie J Orozco, et al.
Blood
|
November 19, 2015
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment
Johnnie J Orozco, Aimee Kenoyer, Ethan R Balkin, et al.
Blood
|
November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies
Damian J Green, Shyril O'Steen, Yukang Lin, et al.
Page
of 28